Setareh Seyedkazemi - 15 May 2025 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
CHIEF DEVELOPMENT OFFICER
Signature
/s/ Aneta Fergson, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
15 May 2025
Net transactions value
-$1,848
Form type
4
Filing time
16 May 2025, 16:45:24 UTC
Previous filing
27 Feb 2025
Next filing
20 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Seyedkazemi Setareh CHIEF DEVELOPMENT OFFICER C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY /s/ Aneta Fergson, Attorney-in-Fact 16 May 2025 0001903088

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADVM Common Stock Sale $1,848 -924 -6.3% $2.00 13,768 15 May 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units.
F2 Price reported is a weighted-average sale price. The shares were sold at prices ranging from $1.98 to $2.01. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.